BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 26994023)

  • 1. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
    Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
    J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
    Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
    Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
    Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
    Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
    Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
    Croce S; Chibon F
    Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
    Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
    Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
    Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
    Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis.
    Cao HY; Yang S; Wang S; Deng LY; Lou JY
    Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28340268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Abnormality of TOP2A expression and its gene copy number variations in neuroblastic tumors].
    Chen JM; Zhou CJ; Ma XL; Guan DD; Yang LY; Yue P; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2016 Nov; 45(11):748-754. PubMed ID: 27821228
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
    Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
    Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXO3a deregulation in uterine smooth muscle tumors.
    de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
    Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.